Zynerba Pharmaceuticals, Inc.
ZYNE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $23 | $113 | $89 | $133 |
| - Cash | $51 | $68 | $59 | $70 |
| + Debt | $0 | $1 | $0 | $0 |
| Enterprise Value | -$28 | $46 | $30 | $63 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$35 | -$36 | -$52 | -$34 |
| % Margin | – | – | – | – |
| Net Income | -$35 | -$38 | -$50 | -$31 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.82 | -0.96 | -1.87 | -1.43 |
| % Growth | 14.6% | 48.7% | -30.8% | – |
| Operating Cash Flow | -$23 | -$33 | -$41 | -$35 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$23 | -$34 | -$42 | -$35 |